Better Drugs to Market Faster

Denovicon seamlessly integrates AI, machine learning, generative therapeutic design, and physics-based approaches (e.g., quantum chemistry, statistical mechanics, molecular dynamics, and free-energy methods) into its (hybrid) computational drug discovery platform. With it, a vast amount of chemical space (~1027 molecules) is quickly and accurately triaged, while only the most desirable analogs are transformed into clinical candidates. We are currently focused on small-molecule therapeutics for a variety of targets in the DNA damage response (DDR) pathways and immuno-oncology. In particular, we are progressing first-in-class molecules that selectively target PARP1 and PARP2 for various diseases in oncology, immunology, neuroscience, and cardiovascular, as well as PARP7 for multiple oncology indications.
News
Denovicon Founder Presents at Drug Discovery Chemistry 2023
Denovicon Founder Presents at Biovia UGM 2022
Denovicon Founder Presents at SLAS 2022
Denovicon Participates in BIO Partnering at JPM 2022
Denovicon Founder Speaks at Lab of the Future Panel on AI in Drug Discovery
Denovicon Founder Speaks at Rady’s Careers in Biotech Panel
Denovicon Partners with Scientist.com to Accelerate & Improve the Drug Discovery Process